NYSE:CTVA

Corteva, Inc. (NYSE: CTVA) announced a common stock dividend of $0.18 cents per share, payable June 15, 2026, to the Company’s shareholders of record on June 1, 2026.
Corteva announced that its Board of Directors approved a quarterly common stock dividend of $0.18 per share. The dividend will be paid on March 16, 2026, to shareholders of record as of March 2, 2026.

Separately, EIDP, Inc., a wholly owned subsidiary of Corteva and formerly known as E. I. du Pont de Nemours and Company, declared regular preferred stock dividends. The company approved a dividend of $1.12½ per share on its $4.50 series preferred stock and $0.87½ per share on its $3.50 series preferred stock. Both preferred dividends are payable on April 24, 2026, to stockholders of record on April 2, 2026.

Source: Company announcement
Corteva and bp announced the launch of Etlas, a 50:50 joint venture focused on producing biofuel feedstocks from crops such as canola, mustard, and sunflower to support sustainable aviation fuel and renewable diesel production. The venture targets annual feedstock output of around one million metric tonnes by the mid-2030s, with initial supply expected in 2027, leveraging Corteva’s seed technology expertise and bp’s downstream fuel capabilities to meet rising global biofuel demand.
Corteva introduces goltrevo bioinsecticide and varpelgo active for sustainable pest control

Corteva Agriscience (NYSE: CTVA) announced two new nature-inspired insect management solutions to help farmers protect yield across major global crops. The company introduced Goltrevo, its first bioinsecticide, and Varpelgo active, a next-generation insecticide designed using natural models.

Goltrevo is a microbial-based, broad-spectrum bioinsecticide derived from the fungus *Beauveria bassiana 203* and targets sap-feeding and chewing insects such as aphids, whiteflies, stinkbugs, and corn leafhoppers. It offers improved shelf life, low resistance potential, and applicability to a wide range of crops, with commercial rollout expected in Latin America by 2027 pending approvals.

Varpelgo active, inspired by the naturally occurring Qalcova active, will provide highly effective control of chewing pests including moths, armyworms, beetles, and borers. It will also serve as a seed-applied technology for wireworm protection. With a favorable ecological profile, low use rates, and compatibility with integrated pest management programs, Varpelgo is expected to launch in Asia Pacific and Latin America in the early 2030s.

Corteva said the new products reflect its strategy to expand biological and sustainable crop protection offerings while enhancing farmer productivity and supporting global food security. Source: Corteva Agriscience press release, November 5, 2025.
Corteva, Inc. (NYSE: CTVA) today announced it will release its third quarter 2025 earnings on Tuesday, November 4, 2025, after the stock market close via press release and its website.
Corteva announced plans to split into two independent, publicly traded companies by the second half of 2026, creating “New Corteva” focused on crop protection and “SpinCo” focused on seeds, in a tax-free transaction aimed at sharpening strategic focus and unlocking shareholder value.
Corteva, Inc. (NYSE: CTVA) announced it will release its second quarter 2025 financial results after market close on Wednesday, August 6, 2025. The company will host a live webcast to discuss the results on Thursday, August 7, at 9:00 a.m. Eastern Time.
Corteva, Inc. (NYSE: CTVA) announced its Board of Directors has authorized a common stock dividend of $0.17 cents per share, payable June 16, 2025, to the Company's shareholders of record on June 2, 2025.
Corteva, Inc. (NYSE: CTVA) announced it will release its first quarter 2025 earnings on Wednesday, May 7, 2025, after the stock market close via press release and its website. The earnings will be presented in a live webcast on Thursday, May 8, 2025, at 9:00 a.m. Eastern Time.
Corteva, Inc. (NYSE: CTVA) announced that Dr. Rebecca Liebert has informed the Board of Directors of her decision to resign from her position as a director, effective February 28, 2025. Dr. Liebert’s departure is to pursue other opportunities and is not due to any disagreement with management or the Board regarding the company’s operations, policies, or practices.

Following her resignation, the Board has decided to reduce its size from thirteen to twelve directors. The company expressed gratitude for Dr. Liebert’s service and contributions to the Board.